Toyota|$17.84 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.82 (¥3,935)-0.63%▼ (in JPY terms)
SoftBank|$29.62 (¥4,695)-3.10%▼ (in JPY terms)
MUFG|$21.64 (¥3,430)-1.38%▼ (in JPY terms)
Keyence|$505.71 (¥80,160)-1.54%▼ (in JPY terms)
Nintendo|$54.32 (¥8,610)+0.81%▲ (in JPY terms)
NTT|$1.10 (¥175)-0.06%▼ (in JPY terms)
Takeda|$39.56 (¥6,271)+0.43%▲ (in JPY terms)
Tokyo Electron|$64.51 (¥10,225)-1.21%▼ (in JPY terms)
Recruit|$116.65 (¥18,490)-1.52%▼ (in JPY terms)
ITOCHU|$14.55 (¥2,307)-0.58%▼ (in JPY terms)
Honda|$11.41 (¥1,809)+0.06%▲ (in JPY terms)
Shin-Etsu|$37.49 (¥5,942)-0.40%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)+0.00%▲ (in JPY terms)
Fast Retailing|$468.49 (¥74,260)+0.56%▲ (in JPY terms)
Toyota|$17.84 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.82 (¥3,935)-0.63%▼ (in JPY terms)
SoftBank|$29.62 (¥4,695)-3.10%▼ (in JPY terms)
MUFG|$21.64 (¥3,430)-1.38%▼ (in JPY terms)
Keyence|$505.71 (¥80,160)-1.54%▼ (in JPY terms)
Nintendo|$54.32 (¥8,610)+0.81%▲ (in JPY terms)
NTT|$1.10 (¥175)-0.06%▼ (in JPY terms)
Takeda|$39.56 (¥6,271)+0.43%▲ (in JPY terms)
Tokyo Electron|$64.51 (¥10,225)-1.21%▼ (in JPY terms)
Recruit|$116.65 (¥18,490)-1.52%▼ (in JPY terms)
ITOCHU|$14.55 (¥2,307)-0.58%▼ (in JPY terms)
Honda|$11.41 (¥1,809)+0.06%▲ (in JPY terms)
Shin-Etsu|$37.49 (¥5,942)-0.40%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)+0.00%▲ (in JPY terms)
Fast Retailing|$468.49 (¥74,260)+0.56%▲ (in JPY terms)

DAIICHI SANKYO COMPANY,LIMITED

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer in China (264KB) will open in a new window as a PDF file.”

by

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuz … 続きを読む

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for the first-line treatment of non-small cell lung cancer with HER2 gene mutations (270.9KB) will be displayed in a new window as a PDF file.”

by

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deru … 続きを読む

2026-07-27 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer (260KB) will open in a new window as a PDF file.”

by

2026-07-27 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of datopotamab deruxtecan (Dato-DXd/DS-1062) as a first-line treatment for triple-negative breast cancer (248.5KB) will open in a new window as a PDF file.”

by

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

Contact